Johnson & Johnson Price Target Steady at $252.87 on Pipeline Optimism, Policy Risks

Analysts maintain a $252.87 price target for Johnson & Johnson (JNJ) stock, according to recent research from Simply Wall St. The steady target reflects a mix of optimism around the company's drug pipeline (notably Icotyde and Inlexzo) and caution over policy and partnership headwinds.

Recommendation Change

The price target remains unchanged at $252.87, with no upgrade or downgrade. The consensus recommendation is "Hold" or equivalent.

Analyst Rationale

Analysts highlight the potential of the pipeline, especially Icotyde and Inlexzo, which could drive future revenue. However, policy risks and partnership challenges may affect execution.

Context

JNJ shares have traded steadily recently, with investors focused on clinical trial results and regulatory developments. Other analysts show mixed views but the target remains anchored.

Conclusion

JNJ stock appears fairly valued, with pipeline optimism offsetting policy risks. Investors should monitor healthcare policy changes and partnership outcomes.